Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 819 results for "novartis ag"

Novartis eager for more Israeli investments

Novartis eager for more Israeli investments

Novartis Global Strategic Partnership head Marie Lindner spoke to "Globes" ahead of her visit to Tel Aviv later this month. "I manage the strategic cooperation team, and if that's not clear enough, it also took us a little time to define ... Globes, 2 hours ago
NOVARTIS : eager for more Israeli investments 4 Traders, 52 minutes ago

Novartis AG (NVS) Receives Hold Rating from Leerink Swann

Leerink Swann restated their hold rating on shares of Novartis AG (NYSE:NVS) in a research report released on Monday morning, Analyst Ratings Net reports. Novartis AG (NYSE:NVS) traded down 0.88% during trading on Monday, reaching $76.16. 1,875,185 ...
 SleekMoney38 minutes ago Novartis AG (NVS) Stock Rating Reaffirmed by Leerink Swann  American Banking News - Earnings1 hour ago Novartis AG (NVS) Forecasted to Earn FY2016 Earnings of $4.94 Per Share  Ticker Report3 days ago FY2016 EPS Estimates for Novartis AG (NVS) Reduced by Analyst  WKRB News3 days ago

Delaney Dennis R Purchases Shares of 17,030 Novartis AG (NVS)

Delaney Dennis R purchased a new stake in Novartis AG (NYSE:NVS) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 17,030 shares of the company's stock, valued at ...
 WKRB News4 hours ago Johnson Investment Counsel Inc. Buys 1,365 Shares of Novartis AG (NVS)  WKRB News8 hours ago Voya Financial Advisors Inc. Has $1,143,000 Stake in Novartis AG (NVS)  Mideast Time1 day ago First National Bank of Omaha Purchases 23,365 Shares of Novartis AG (NVS)  Mideast Time1 day ago

Novartis AG's Chief Ethics and Compliance Officer Retires

Novartis AG's chief ethics and compliance officer, Eric Cornut, is retiring from his role, according to a company spokesman. Mr. Cornut—who reported directly to Chief Executive Joe Jimenez—had been in the post since August 2014, when Novartis ...
 BioSpace5 hours ago Shannon Klinger to Replace Eric Cornut as Novartis's Ethics Officer  4 Traders8 hours ago Novartis Feels the Effect Of Drop in Gleevec Sales -- WSJ  4 Traders1 week ago Novartis AG 1Q 2016 -- Forecast  4 Traders2 weeks ago
Pharmaceutical Business Review

BRIEF-Novartis says Afinitor gets nod in EU for some GI, lung neuroendocrine tumors

April 29 Novartis Ag * Novartis says afinitor recommended by chmp for european union approval to treat select gi and lung neuroendocrine tumors Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom) Our top ...
 Reuters UK4 days ago Novartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumors  Bloomberg4 days ago Novartis' Ilaris wins three FDA breakthrough designations to treat periodic fever syndromes  Pharmaceutical Business Review5 days ago Novartis Ilaris receives FDA breakthrough status to treat fever syndromes  Reuters UK6 days ago
Digital Journal

Novartis Heart Drug Gets Endorsed by NICE, But Not for Everyone

Entresto backed for about 100,000 people with heart failure Patients must first take hypertension drugs, NICE rules A Novartis AG heart drug that's struggled to gain acceptance in the U.S. won the backing of a U.K. panel as a cost-effective ...
 Bloomberg6 days ago Novartis profit falls as blockbuster cancer drug sales drop  Gulf News1 week ago Mixed news for Novartis  Digital Journal1 week ago Europe warms to new Novartis heart drug amid glacial U.S. Sales  LifeHealthPro1 week ago

MorphoSys announces its partner Novartis' phase 2b/3 study of bimagrumab in sporadic inclusion body myositis fails to meet primary endpoint

MorphoSys AG, a German biotechnology company, announced that its partner Novartis has confirmed that a phase 2b/3 study examining bimagrumab (BYM338) in sporadic inclusion body myositis (sIBM) did not meet its primary endpoint. Data are currently ...
 PharmaBiz1 week ago Novartis AG's Breakthrough Muscle Drug Fails to Meet Primary Goal in Patients with sIBM  BioSpace1 week ago
Bidness Etc

Novartis AG (ADR) Under Pressure on Q1 Revenue Decline

Novartis AG (ADR) ( NYSE:NVS ) has reported financial results for the first quarter of fiscal year 2016 (1QFY16) with a decline in both, its earnings and revenues. The drug maker continues to struggle with its eye-care business and aging cancer drug ...
 Bidness Etc1 week ago Novartis AG (ADR) First-Quarter Earnings: What to Expect?  Bidness Etc1 week ago

Novartis AG (NVS) Joseph Jimenez on Q1 2016 Results - Earnings Call Transcript

Novartis AG (NYSE: NVS ) Q1 2016 Earnings Call April 21, 2016 8:00 am ET Executives Joseph Jimenez - Chief Executive Officer Samir Shah - Global Head-Investor Relations F. Michael Ball - Chief Executive Officer, Alcon, Inc. ...
 Seeking Alpha1 week ago MorphoSys' (MPSYF) CEO Simon Moroney on Q1 2016 Results - Earnings Call Transcript  Seeking Alpha3 hours ago

Novartis Profit Beats Estimates Amid Loss of Patent on Key Drug

(Bloomberg) -- Novartis AG reported first-quarter earnings that beat analysts estimates even after losing patent protection on its best-selling cancer medicine Gleevec. Profit fell to $1.17 a share, excluding some items, the Basel, ...
 La Repubblica1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - novartis ag
Get updated on latest news & your favorite topics right in your inbox!
More     Less